Arexvy in Lung and Renal Transplant Recipients vs Healthy Controls

Phase 2, randomised, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV) (3 arms), sponsored by GSK. Primary endpoints: RSV-A serum neutralizing titers MGI post-Dose 2 over post-Dose 1 in renal and lung solid organ transplant patients in the 2-dose group and RSV-B serum neutralizing titers MGI post-Dose 2 over post-Dose 1 in renal and lung solid organ transplant patients in the 2-dose group. Started Oct 2023; status: completed.